Usefulness of Whole-Body 18F-FDG PET in Patients with Suspected Metastatic Brain Tumors
Hwan-Jeong Jeong, MD1,2,3,
June-Key Chung, MD1,2,
Yu Kyeong Kim, MD1,
Chae Yong Kim, MD4,
Dong Gyu Kim, MD4,
Jae Min Jeong, PhD1,2,
Dong Soo Lee, MD1,
Hee Won Jung, MD4 and
Myung Chul Lee, MD1
1 Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea
2 Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
3 Department of Nuclear Medicine, Wonkwang University, College of Medicine, Iksan, Korea
4 Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea

View larger version (106K):
[in a new window]
|
FIGURE 1. A 61-y-old woman with squamous cell carcinoma in lung and metastasis to brain. (A) Brain MR image shows enhanced mass in right cerebellar hemisphere (white arrowhead). (B) 18F-FDG PET image shows hypermetabolic lesion in same site as on MR image (black arrowhead). (C) Whole-body 18F-FDG PET image shows hypermetabolic lesions in right hilum, left lung (solid-line arrows), and left proximal humerus (dotted-line arrow). (D) Chest CT image certifies PET findings in chest region (white arrows) but not in humerus.
|
|

View larger version (92K):
[in a new window]
|
FIGURE 2. A 52-y-old man with malignant melanoma and metastasis to medulla oblongata. (A) Brain MR image shows small-sized, enhanced mass in medulla oblongata (white arrowhead). (B) 18F-FDG PET image shows hypermetabolic lesion in same site as on MR image (black arrowhead). (C) Whole-body 18F-FDG PET image shows hypermetabolic lesions in right axilla area (solid-line arrow) and left hilum (not shown). Radiologic work-up did not reveal any lesion.
|
|
Copyright © 2002 by the Society of Nuclear Medicine.